Perspectives of Proteomics in Respiratory Allergic Diseases

Proteomics in respiratory allergic diseases has such a battery of techniques and programs that one would almost think there is nothing impossible to find, invent or mold. All the resources that we document here are involved in solving problems in allergic diseases, both diagnostic and prognostic treatment, and immunotherapy development. The main perspectives, according to this version, are in three strands and/or a lockout immunological system: (1) Blocking the diapedesis of the cells involved, (2) Modifications and blocking of paratopes and epitopes being understood by modifications to antibodies, antagonisms, or blocking them, and (3) Blocking FceRI high-affinity receptors to prevent specific IgEs from sticking to mast cells and basophils. These tools and targets in the allergic landscape are, in our view, the prospects in the field. However, there are still many allergens to identify, including some homologies between allergens and cross-reactions, through the identification of structures and epitopes. The current vision of using proteomics for this purpose remains a constant; this is also true for the basis of diagnostic and controlled systems for immunotherapy. Ours is an open proposal to use this vision for treatment.

Automated summary

Proteomics in respiratory allergic diseases offers a wide range of techniques and programs for diagnosis, treatment, and immunotherapy. The main focus is on blocking cell diapedesis, modifying and blocking paratopes and epitopes, and inhibiting FceRI high-affinity receptors to prevent IgE binding. However, there is still a need for identifying allergens and cross-reactions through structural and epitope identification. The use of proteomics remains crucial for diagnostics and controlled immunotherapy systems. It is proposed to utilize this vision for treatment.